Circulation EDITORIAL Global Challenges and Clear Opportunities Article, see p 806 Katharine A. French, MD Athena Poppas, MD heumatic heart disease (RHD) is a disease of poverty. Following the near eradication of rheumatic fever and RHD in the developed world and the Remergence of competing large global epidemics such as AIDS, tuberculosis, and malaria, research and investment for the control of rheumatic fever and RHD worldwide declined. However, over the past decade, RHD has reemerged as a pri- ority in global health. The World Health Organization and the World Heart Federa- tion have called for a 25% reduction in mortality because of cardiovascular causes, including RHD, by 2025. Contemporary studies have begun to shed light on the enormous burden of RHD that persists in countries with emerging and developing economies. The high- est prevalence of RHD has been reported in India, China, Pakistan, Indonesia, and the Democratic Republic of Congo—accounting for 73% of global cases. Within 20 countries where RHD remains endemic, the age-standardized prevalence is es- timated at >1% and greatest in women of childbearing age. The economic im- pact of RHD in these regions is equally as unsettling. Disability-adjusted life years because of RHD is estimated at
Circulation – Wolters Kluwer Health
Published: Feb 20, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud